Company profile
ATOSSA THERAPEUTICS, INC.
NASDAQ:ATOSBiotechnology: Pharmaceutical Preparations
Clinical trials (5)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05607004 | phase2 | active_not_recruiting | 2023-02-14 | 2026-11-01 | Atossa Therapeutics, Inc. | (Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer |
| NCT02540330 | phase2 | terminated | 2016-03-01 | 2020-08-13 | Atossa Therapeutics, Inc. | A Pre-Surgical PK Study of IM and Intraductally Delivered Fulvestrant |
| NCT04519788 | phase1 | completed | 2020-08-07 | 2020-12-08 | Atossa Therapeutics, Inc. | AT-301 Nasal Spray in Healthy Adults |
| NCT05068388 | phase2 | completed | 2021-12-21 | 2024-06-14 | Atossa Therapeutics, Inc. | Effect of Oral (Z)-Endoxifen in Premenopausal Women With Measurable Breast Density |
| NCT04616430 | phase2 | completed | 2018-04-09 | 2018-09-10 | Atossa Therapeutics, Inc. | Topical Endoxifen in Women |
FDA applications (0)
No records yet.